Advances in Adverse Reactions of Biologics and Small Molecule Drugs in Treatment of Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2024.12.008
- VernacularTitle:生物制剂和小分子药物治疗炎症性肠病不良反应的研究进展
- Author:
Xiaojuan WANG
1
;
Bingxia PENG
;
Shixue DAI
;
Weihong SHA
Author Information
1. 赣南医科大学第一临床医学院(341000)
- Publication Type:Journal Article
- Keywords:
Inflammatory Bowel Disease;
Biological Agents;
Small Molecule Drugs;
Adverse Reactions
- From:
Chinese Journal of Gastroenterology
2024;29(12):745-750
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease(IBD)is an immune-mediated inflammatory disorder with high heterogeneity.The safety of its treatment,particularly adverse reactions,is a crucial area that physicians need to focus on.Currently,the biologic agents and small molecule drugs for treating IBD,such as anti-tumor necrosis factor-α agents,anti-integrin agents,interleukin(IL)-12/IL-23-targeting biologic agents,Janus kinase(JAK)inhibitors,and sphingosine-1-phosphate(S1P)receptor modulators,can induce both acute and chronic adverse reactions.Chronic adverse reactions mainly manifest as opportunistic infections,malignancies in different organs,especially lymphomas,as well as adverse reactions in the cardiovascular and nervous systems.The adverse reactions caused by the above-mentioned drugs exhibit both homogeneity and heterogeneity.Employing artificial intelligence(AI)techniques to summarize the patterns of biologic agents and small molecule drugs in the treatment of IBD and constructing models to predict the adverse reactions in heterogeneous individuals might be an important technological approach to enhance the safety of biologic treatments for IBD.This article reviews the research progress on the adverse reactions of biologic agents and small molecule drugs in the treatment of IBD.
